Search research articles
Contact Us
Filters
Showing results (11-20 of 40) with videos related to
Page
of 4
Sort By:
American Heart Journal
|
March 1, 2014
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium
Philip T Sager, Gary Gintant, J Rick Turner, et al.
American Heart Journal
|
December 12, 2017
Drug-induced cardiac abnormalities in premature infants and neonates
Luana Pesco-Koplowitz, Gary Gintant, Robert Ward, et al.
Plos One
|
July 9, 2019
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization
Werner Bystricky, Christoph Maier, Gary Gintant, et al.
Journal of Pharmacological and Toxicological Methods
|
July 18, 2006
ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation
Laurie A Hanson, Alan S Bass, Gary Gintant, et al.
Circulation Research
|
September 20, 2019
Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association
Gary Gintant, Paul Burridge, Lior Gepstein, et al.
Journal of Pharmacological and Toxicological Methods
|
July 1, 2018
CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
Rob Wallis, Charles Benson, Borje Darpo, et al.
Journal of Pharmacological and Toxicological Methods
|
June 11, 2016
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress
Thomas Colatsky, Bernard Fermini, Gary Gintant, et al.
Therapeutic Innovation & Regulatory Science
|
August 31, 2018
Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting
David G Strauss, Gary Gintant, Zhihua Li, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 14, 2016
Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats
Christopher M Harris, Scott Mittelstadt, Patricia Banfor, et al.
American Heart Journal
|
December 7, 2019
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 40) with videos related to
Sort By:
Page
of 4
American Heart Journal
|
March 1, 2014
Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium
Philip T Sager, Gary Gintant, J Rick Turner, et al.
American Heart Journal
|
December 12, 2017
Drug-induced cardiac abnormalities in premature infants and neonates
Luana Pesco-Koplowitz, Gary Gintant, Robert Ward, et al.
Plos One
|
July 9, 2019
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization
Werner Bystricky, Christoph Maier, Gary Gintant, et al.
Journal of Pharmacological and Toxicological Methods
|
July 18, 2006
ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation
Laurie A Hanson, Alan S Bass, Gary Gintant, et al.
Circulation Research
|
September 20, 2019
Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association
Gary Gintant, Paul Burridge, Lior Gepstein, et al.
Journal of Pharmacological and Toxicological Methods
|
July 1, 2018
CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
Rob Wallis, Charles Benson, Borje Darpo, et al.
Journal of Pharmacological and Toxicological Methods
|
June 11, 2016
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress
Thomas Colatsky, Bernard Fermini, Gary Gintant, et al.
Therapeutic Innovation & Regulatory Science
|
August 31, 2018
Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting
David G Strauss, Gary Gintant, Zhihua Li, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 14, 2016
Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats
Christopher M Harris, Scott Mittelstadt, Patricia Banfor, et al.
American Heart Journal
|
December 7, 2019
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]
Jonathan H Seltzer, Gary Gintant, Laleh Amiri-Kordestani, et al.
Page
of 4